Combining Dapagliflozin and Eplerenone Further Reduces Albuminuria in CKD
Study findings suggest the nephroprotective effects of both drug classes are complementary.
Study findings suggest the nephroprotective effects of both drug classes are complementary.
Study findings highlight an “unmet need” for newer therapies.
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
These SCS devices were cleared based on data from a randomized controlled trial published in the journal Diabetes Care in 2014.
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.
Findings among patients with type 2 diabetes and history of cardiovascular disease or current kidney disease
Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
More than two-thirds of patients experienced a more than 5% weight loss with 12 months of etelcalcetide treatment.